Naglazyme

Quick orientation

Naglazyme (galsulfase) is a recombinant human N-acetylgalactosamine 4-sulfatase enzyme replacement therapy developed by BioMarin for mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). The US Food and Drug Administration approved Naglazyme in May 2005 to improve walking and stair-climbing capacity in patients with MPS VI, and it remains the only FDA-approved enzyme replacement therapy for this lysosomal storage disorder. It is administered as a weekly intravenous infusion at 1 mg/kg over approximately four hours, with pre-medication for infusion-associated reactions. Naglazyme is prescribed and monitored by medical geneticists or metabolic-disease specialists, with infusions typically delivered in hospital infusion suites or accredited home-infusion programmes.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Naglazyme

1. Patient or treating physician submits an intake at the patient portal.
2. Reserve Meds clinical team verifies appropriateness for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific named-patient documentation is prepared.
5. Naglazyme is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.

Access by country

Reserve Meds publishes a detailed country access guide for Naglazyme in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.

Start a request for Naglazyme

Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.

Start your case Or message us on WhatsApp